Trexquant Investment LP bought a new stake in Teladoc Health, Inc. (NYSE:TDOC - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 303,743 shares of the health services provider's stock, valued at approximately $2,761,000. Trexquant Investment LP owned 0.18% of Teladoc Health at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in TDOC. Vanguard Group Inc. lifted its stake in Teladoc Health by 5.9% in the fourth quarter. Vanguard Group Inc. now owns 18,463,155 shares of the health services provider's stock worth $167,830,000 after purchasing an additional 1,029,829 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Teladoc Health by 20,936.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 426,206 shares of the health services provider's stock worth $3,874,000 after purchasing an additional 424,180 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Teladoc Health by 18.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,443,713 shares of the health services provider's stock worth $22,213,000 after purchasing an additional 384,528 shares during the last quarter. Wealthfront Advisers LLC bought a new stake in shares of Teladoc Health during the fourth quarter worth $3,364,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Teladoc Health during the fourth quarter valued at $2,859,000. Institutional investors own 76.82% of the company's stock.
Insider Activity at Teladoc Health
In related news, insider Adam C. Vandervoort sold 11,011 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $8.42, for a total value of $92,712.62. Following the completion of the transaction, the insider now owns 64,308 shares in the company, valued at $541,473.36. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.95% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada lifted their price objective on shares of Teladoc Health from $11.00 to $12.00 and gave the company an "outperform" rating in a report on Friday, January 24th. Oppenheimer decreased their price target on shares of Teladoc Health from $14.00 to $12.00 and set an "outperform" rating for the company in a research note on Friday, January 24th. Piper Sandler dropped their price objective on Teladoc Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Bank of America decreased their target price on Teladoc Health from $9.50 to $8.00 and set a "neutral" rating for the company in a research report on Friday. Finally, The Goldman Sachs Group dropped their price target on Teladoc Health from $16.00 to $13.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Eleven analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Teladoc Health has a consensus rating of "Hold" and a consensus target price of $10.94.
Check Out Our Latest Analysis on TDOC
Teladoc Health Stock Up 0.2 %
Shares of TDOC stock traded up $0.02 during trading hours on Friday, reaching $7.26. 5,040,718 shares of the company's stock were exchanged, compared to its average volume of 6,248,500. Teladoc Health, Inc. has a fifty-two week low of $6.61 and a fifty-two week high of $15.21. The stock's 50 day moving average is $9.73 and its 200-day moving average is $9.69. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -1.26 and a beta of 1.73.
Teladoc Health (NYSE:TDOC - Get Free Report) last announced its earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The business had revenue of $640.49 million for the quarter, compared to analyst estimates of $639.44 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. Analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current fiscal year.
Teladoc Health Company Profile
(
Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
See Also
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
